Most Popular Articles : Melanoma Research

Journal Logo

Most Popular Articles

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors

Ismail, Rawa K.; Suijkerbuijk, Karijn P.M.; de Boer, Anthonius; More

Melanoma Research. 32(6):460-468, December 2022.

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

Manzano, Jose L.; Martin-Liberal, Juan; Fernández-Morales, Luis A.; More

Melanoma Research. : March 28, 2023

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis

Ziegler, Johanna S.; Kroeze, Stephanie; Hilbers, Marie-Luise; More

Melanoma Research. 30(6):552-561, December 2020.

Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

Vuillamy, Chloé; Arnault, Jean-Philippe; Fumery, Mathurin; More

Melanoma Research. 33(3):192-198, June 2023.

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma

Brunsgaard, Elise K.; Bowles, Tawnya L.; Asare, Elliot A.; More

Melanoma Research. 33(3):184-191, June 2023.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

Hodi, F. Stephen; Chapman, Paul B.; Sznol, Mario; More

Melanoma Research. 31(1):67-75, February 2021.

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Vera Aguilera, Jesus; Paludo, Jonas; McWilliams, Robert R.; More

Melanoma Research. 30(4):364-375, August 2020.

Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging

Wisco, Oliver J.; Marson, Justin W.; Litchman, Graham H.; More

Melanoma Research. 32(2):98-102, April 2022.

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Bisschop, Cornelis; ter Elst, Arja; Bosman, Lisette J.; More

Melanoma Research. 28(2):96-104, April 2018.

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients

Fortman, Dylan; Avellan, Maria G. Pazan; Hurd, Drew; More

Melanoma Research. 33(2):136-148, April 2023.

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment

Cybulska-Stopa, Bożena; Piejko, Karolina; Ostaszewski, Krzysztof; More

Melanoma Research. 33(3):208-217, June 2023.

Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade

Anderson, Katie L.; Snyder, Kristin M.; Ito, Daisuke; More

Melanoma Research. 30(2):147-158, April 2020.

Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective

Buja, Alessandra; Rugge, Massimo; De Luca, Giuseppe; More

Melanoma Research. 32(5):353-359, October 2022.

Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Ismail, Rawa K.; Sikkes, Nienke O.; Wouters, Michel W.J.M.; More

Melanoma Research. 31(1):58-66, February 2021.

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013–2016

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Ascierto, Paolo A.; Bastholt, Lars; Ferrucci, Pier F.; More

Melanoma Research. 28(4):333-340, August 2018.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Hintzsche, Jennifer D.; Gorden, Nicholas T.; Amato, Carol M.; More

Melanoma Research. 27(3):189-199, June 2017.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma

Shah, Shalin; Luke, Jason J.; Jacene, Heather A.; More

Melanoma Research. 28(6):605-610, December 2018.

The molecular profile of mucosal melanoma

Mikkelsen, Lauge Hjorth; Maag, Emil; Andersen, Mette Klarskov; More

Melanoma Research. 30(6):533-542, December 2020.

MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin

Bønnelykke-Behrndtz, Marie L.; Steiniche, Torben; Damsgaard, Tine E.; More

Melanoma Research. 25(2):113-118, April 2015.

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Holtkamp, Lodewijka H.J.; Chakera, Annette H.; Fung, Sebastian; More

Melanoma Research. 30(4):358-363, August 2020.